Skip to main content

Stevanato Group S.p.A. (STVN)

NYSE: STVN · IEX Real-Time Price · USD
24.96 0.36 (1.46%)
Oct 21, 2021 1:38 PM EDT - Market open
Market Cap7.30B
Revenue (ttm)820.56M
Net Income (ttm)123.36M
Shares Out292.43M
EPS (ttm)0.42
PE Ratio59.17
Forward PE46.95
Dividendn/a
Ex-Dividend Daten/a
Volume147,546
Open24.34
Previous Close24.60
Day's Range24.34 - 25.30
52-Week Range16.61 - 29.18
Betan/a
AnalystsStrong Buy
Price Target28.97 (+16.1%)
Est. Earnings DateNov 18, 2021

About STVN

Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. We deliver an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Our core capabilities in scientific research and development, our commitment to technical innovation and our engineering excellence are central to our ability to offer value...

IndustryMedical Instruments & Supplies
IPO DateJul 16, 2021
CEOFranco Moro
Employees4,344
Stock ExchangeNYSE
Ticker SymbolSTVN
Full Company Profile

Financial Performance

In 2020, STVN's revenue was 662.04 million, an increase of 23.39% compared to the previous year's 536.54 million. Earnings were 78.51 million, an increase of 100.28%.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 8 analysts, the average rating for STVN stock is "Strong Buy." The 12-month stock price forecast is 28.97, which is an increase of 16.07% from the latest price.

Price Target
$28.97
(16.07% upside)
Analyst Consensus: Strong Buy

News

Stevanato Group Wins Pharma Innovation Award For AI-ready Vision Robot Unit (VRU)

PIOMBINO DESE (PD), Italy--(BUSINESS WIRE)--Stevanato Group (NYSE:STVN) (“the Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnolog...

2 days ago - Business Wire

Stevanato Group Initiates Construction on New U.S. Facility

PIOMBINO DESE (PD), Italy--(BUSINESS WIRE)--Stevanato Group (NYSE:STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life scien...

2 weeks ago - Business Wire

Stevanato Group Announces Second Quarter 2021 Financial Results

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, a...

2 months ago - Business Wire

Stevanato Group Announces Underwriters' Partial Exercise of Over-Allotment Option

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology ...

2 months ago - Business Wire

Stevanato Group to Report Second Quarter Financial Results on August 19

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, an...

2 months ago - Business Wire

Stevanato Group makes NYSE debut

Franco Stevanato joins 'The Exchange' to speak about his company's NYSE debut today. The Stevanato Group makes glass vials and other components critical to distributing Covid-19 vaccines.

3 months ago - CNBC Television

Vaccine vial maker Stevanato valued at over $5 billion in NYSE debut

(Reuters) -Shares of Italy's Stevanato Group S.p.A., which makes glass vials for COVID-19 vaccines and other healthcare products, fell more than 20% in their New York Stock Exchange debut, giving the co...

3 months ago - Reuters

Stevanato Group Celebrates Initial Public Offering and First Day of Public Trading on New York Stock Exchange (NYSE)

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (the “Company”) today celebrates its debut on the New York Stock Exchange under the ticker symbol “STVN.” Founded by Giovanni Stevanato in 1...

3 months ago - Business Wire

Vaccine vial maker Stevanato raises $672 million in U.S. IPO

Stevanato Group S.p.A., an Italian maker of glass vials for COVID-19 vaccines and other healthcare products, raised $672 million in a downsized initial public offering on Thursday.

3 months ago - Reuters

Stevanato Group Announces Pricing of Initial Public Offering

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology ...

3 months ago - Business Wire

Stevanato Group Launches Roadshow for Proposed Initial Public Offering

Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced...

3 months ago - Business Wire

Italy's Stevanato Group files for U.S. IPO

Italy's Stevanato Group, manufacturer of glass vials for COVID-19 vaccines and other healthcare products, filed for a U.S. initial public offering on Monday, as the pandemic boosted the demand for some ...

4 months ago - NASDAQ

Stevanato Group Files Registration Statement for Proposed Initial Public Offering

Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today ann...

4 months ago - Business Wire

Stevanato Group IPO Registration Document (S-1)

Stevanato Group S.p.A. has filed to go public with an IPO on the New York Stock Exchange (NYSE).

4 months ago - SEC